25C-NBOMe (2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine) is a synthetic phenethylamine psychedelic belonging to the NBOMe series --- a family of compounds created by attaching an N-2-methoxybenzyl group to the well-known 2C-x phenethylamines. Specifically, 25C-NBOMe is the NBOMe derivative of2C-C (Shulgin's 4-chloro-substituted 2,5-dimethoxyphenethylamine), and it acts as apotent full agonist at the serotonin 5-HT2A receptor with subnanomolar binding affinity (Ki approximately 2.9 nM) .
Like other NBOMe compounds, 25C-NBOMe is active at sub-milligram doses (typically 300--800 micrograms sublingual), making accurate dosing extremely difficult without laboratory-grade equipment. This narrow dosing window, combined with its full agonist pharmacology and unpredictable individual sensitivity, gives the entire NBOMe class asignificantly higher risk profile than classical psychedelics like LSD or psilocybin, which are partial agonists with wider safety margins. Multiple fatalities have been attributed to NBOMe compounds, primarily 25I-NBOMe but also other members of the series .
The subjective experience is broadly similar to other potent phenethylamine psychedelics: vivid visual effects, color intensification, geometric patterning, and stimulation. Compared to its more extensively documented cousin 25I-NBOMe, 25C-NBOMe has received less clinical and forensic attention, though its pharmacological risk profile is considered comparable. It is typically encountered on blotter paper or in liquid solution, and has been sold misrepresented as LSD .
References
Rickli A, et al. Pharmacological characterization of the synthetic cathinones and phenethylamines. Biochem Pharmacol. 2015;103:182-194. Suzuki J, et al. NBOMe: Preliminary data on pharmacology, psychoactive effects, and toxicity. Psychopharmacology. 2015;232:1121-1127. Poklis JL, et al. 25C-NBOMe short characterisation. Forensic Toxicology. 2020;38:530-537.
Safety at a Glance
High Risk- Ehrlich Reagent Test — Critical
- Send a sample to EcstasyData.org, The Loop, or a comparable mass spectrometry testing service for definitive identifi...
- Toxicity: Confirmed Fatalities 25C-NBOMe is directly associated with confirmed human fatalities. Reports of fatal outcomes incl...
- Dangerous with: Cocaine
- Overdose risk: LD50fatal at heavy dosages. It is advised that due to 25C-NBOMe's extreme potency it should not b...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
sublingual
Duration
sublingual
Total: 8 hrs – 10 hrsHow It Feels
Within fifteen minutes of holding the blotter against the gum, the bitter chemical taste has permeated the mouth and a sharp, buzzing energy starts to climb the spine. The onset is faster and more assertive than 25C-NBOH. Heart rate picks up noticeably, and there is an immediate tightening in the peripheral blood vessels -- fingers cool, toes tingle, and the jaw begins to clench. Colors in the visual field start to bleed and intensify, as though the contrast on a screen has been cranked upward while the hue slider shifts freely.
By forty-five minutes, the world has been transformed into a vivid, saturated lightshow. Colors are extraordinarily bright and seem to pulse with their own internal rhythm. Visual geometry appears as flowing, colorful patterns that overlay surfaces with moderate density -- less aggressively mathematical than 25I-NBOMe but more intense than the gentler 2C compounds. Walls breathe, textures ripple, and objects acquire shimmering auras of complementary color. There is a pronounced color-shifting effect where surfaces cycle through hues in slow, mesmerizing waves. The stimulant component is significant but manageable -- a persistent buzzing energy that drives a desire to move, explore, and engage with the environment.
The peak plateau lasts roughly two to three hours and is characterized by strong visual activity paired with a relatively clear headspace. Thoughts move quickly but remain coherent. There is an emotional brightness and a tendency toward laughter and playfulness. Music is dramatically enhanced, with bass frequencies seeming to physically vibrate through the body and melodies acquiring vivid synesthetic color associations. The body load is present but less punishing than 25B-NBOMe or 25I-NBOMe -- vasoconstriction and jaw tension are noticeable without being dominant. Nausea may appear in brief waves but rarely persists.
Compared to classical psychedelics, the duration is compact. Effects begin to diminish around four to five hours after onset, with the visual fireworks dimming to a pleasant shimmer. The stimulant energy gradually dissipates, replaced by a tired but not unpleasant fatigue. The total experience spans five to eight hours. The comedown can leave a feeling of being physically wrung out -- residual tension in the shoulders and jaw, mild dehydration, and occasionally a dull headache. There is often a sense of having attended a particularly vivid light show rather than having undergone a transformative inner journey.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(29)
- Abnormal heartbeat— Abnormal heartbeat (arrhythmia) is any deviation from the heart's normal rhythm — including beats th...
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
- Changes in felt gravity— A distortion of one's proprioceptive sense of gravity in which the perceived direction of gravitatio...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
- Mouth numbing— Mouth numbing is a localized loss of sensation in the tongue, gums, cheeks, and surrounding oral tis...
- Muscle cramp— Muscle cramps are sudden, involuntary, and often painful contractions of muscles that occur as a sid...
- Muscle tension— Persistent partial contractions or tightening of muscles that produces uncomfortable stiffness, cram...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Restless legs— Restless legs is an uncomfortable neurological effect characterized by an irresistible compulsion to...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Stomach cramp— Stomach cramps are sharp, intermittent pains in the abdominal region that can occur when psychoactiv...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Tactile hallucination— Tactile hallucinations are convincing physical sensations experienced without any corresponding exte...
Cognitive & Perceptual Effects
Visual(18)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Environmental cubism— A visual distortion in which the environment and objects within it appear fragmented into geometric,...
- External hallucination— A visual hallucination that manifests within the external environment as though it were physically r...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Recursion— The visual field begins to repeat and nest within itself in a self-similar, fractal-like manner, as ...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(16)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Feelings of impending doom— Feelings of impending doom is the sudden onset of an overwhelming, visceral certainty that something...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
- Language suppression— A diminished ability to formulate, comprehend, or articulate language, ranging from difficulty findi...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Multi-sensory(4)
- Dosage independent intensity— Dosage independent intensity is the uncommon and poorly understood phenomenon in which a person expe...
- Gustatory hallucination— Gustatory hallucinations are phantom taste experiences in which distinct flavors manifest in the mou...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(3)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
25C-NBOMe is a potent partial agonist at serotonin 5-HT2A receptors with high selectivity for the serotonin receptor system over other receptor types. The N-(2-methoxybenzyl) group that defines the NBOMe series dramatically increases 5-HT2A binding affinity through additional interactions with the receptor binding pocket. This increased affinity accounts for the dramatically lower active dose compared to 2C-C.
Comparative Pharmacology within NBOMe Series
Among the three major NBOMe compounds (25I, 25B, 25C), 25C-NBOMe is generally considered to have slightly lower 5-HT2A binding affinity than 25I-NBOMe and roughly comparable affinity to 25B-NBOMe, consistent with the known structure-activity relationship of 4-halogen substitution. However, all three are active at comparable dose ranges and carry similar toxicity profiles.
Additional Receptor Activity
Beyond 5-HT2A, 25C-NBOMe has affinity for 5-HT2C receptors (contributing to anxiety and anxiogenic potential) and activates alpha-adrenergic receptors, producing the vasoconstriction and cardiovascular stimulation that represent the primary mechanism of serious toxicity.
Pharmacokinetics
25C-NBOMe is inactive orally. It is absorbed through oral mucosa following sublingual or buccal administration. Onset is 20–45 minutes, peak effects at 2–3 hours, and total duration approximately 6–10 hours — somewhat shorter than 25I-NBOMe but longer than many other NBOMe analogs. Hepatic CYP450 metabolism is presumed.
Tolerance
Functional tolerance to 25C-NBOMe develops rapidly, with expected cross-tolerance to other serotonergic psychedelics (LSD, psilocybin, mescaline). A minimum of 5–7 days between uses is recommended.
Detection Methods
Urine Detection
25C-NBOMe is not targeted by standard immunoassay-based urine drug screens. However, due to its phenethylamine backbone, there is a theoretical possibility of cross-reactivity with amphetamine immunoassays, though this has not been consistently reported in clinical literature. Specialized LC-MS/MS methods developed for novel psychoactive substances can detect NBOMe compounds and their metabolites in urine for approximately 24 to 48 hours after ingestion, depending on dose and individual metabolism.
Blood and Serum Detection
Blood detection windows for 25C-NBOMe are relatively short. Peak plasma concentrations occur within 30 minutes to 2 hours depending on the route of administration (sublingual absorption is typical for NBOMe compounds). Blood concentrations fall below detectable thresholds within 6 to 16 hours for most methods. LC-MS/MS remains the only reliable analytical approach for serum detection, as the doses involved (typically hundreds of micrograms to low milligrams) produce low absolute concentrations.
Standard Drug Panel Inclusion
25C-NBOMe is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. It is not specifically targeted by any routine workplace or clinical immunoassay. While some structural similarity to amphetamines exists, cross-reactivity on amphetamine panels is inconsistent and cannot be relied upon for either detection or exclusion. Identification requires specific testing at a reference laboratory equipped for novel psychoactive substance analysis.
Confirmatory Methods
Definitive identification of 25C-NBOMe requires LC-MS/MS or high-resolution mass spectrometry (HRMS). GC-MS can also be employed but may require derivatization due to the thermal lability of NBOMe compounds. Reference standards are necessary for quantitative confirmation. Forensic and clinical toxicology laboratories that maintain novel psychoactive substance panels are the only facilities reliably capable of this analysis.
Reagent Testing (Harm Reduction)
Reagent testing is critically important for NBOMe compounds due to their significantly higher toxicity profile compared to classical psychedelics. The Ehrlich reagent shows NO reaction with 25C-NBOMe, which is the single most important distinguishing test: any substance sold as a psychedelic that fails to turn purple with Ehrlich may be an NBOMe compound rather than LSD or a tryptamine. The Marquis reagent produces variable results depending on the specific NBOMe compound, ranging from no reaction to green or brown color changes. The Mecke reagent may produce a brown or dark green reaction. For harm reduction purposes, always testing with Ehrlich first is essential. The absence of a purple Ehrlich reaction is a strong warning sign that the substance is not a lysergamide or tryptamine and may be a potentially dangerous NBOMe compound.
Interactions
| Substance | Status | Note |
|---|---|---|
| Cocaine | Unsafe | — |
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 2C-T-x | Uncertain | — |
| Caffeine | Uncertain | — |
| Cannabis | Uncertain | — |
| DOx | Uncertain | — |
| MDMA | Uncertain | — |
History
Origin and Synthesis
The NBOMe series originated from the doctoral research of Ralf Heim at the Free University of Berlin. Heim's 2003 dissertation, "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur" (Synthesis and Pharmacology of Potent 5-HT2A Receptor Agonists with N-2-Methoxybenzyl Partial Structure), systematically explored how adding an N-2-methoxybenzyl group to existing 2C-x phenethylamines could dramatically enhance their binding affinity at the serotonin 5-HT2A receptor . This structural modification converted compounds with micromolar affinity into nanomolar-range agonists --- creating a new class of extraordinarily potent psychedelic phenethylamines.
Research Chemical Market Emergence
25C-NBOMe and its structural relatives began appearing on the research chemical (RC) market around 2010--2012, initially sold as "legal" alternatives to LSD on blotter paper. The compound gained wider availability following the earlier popularization of25I-NBOMe, which had become one of the most widely distributed novel psychoactive substances globally by 2012 . 25C-NBOMe was typically sold as blotter or in liquid form, often misrepresented as LSD to unsuspecting buyers.
Regulatory Response
As hospitalizations and fatalities linked to NBOMe compounds accumulated, regulatory bodies worldwide moved to schedule the series. The U.S. DEA placed 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe into Schedule I on November 15, 2013, via emergency scheduling . Most European nations, Australia, and numerous other jurisdictions followed with similar bans through 2013--2015.
References
Heim R. Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Dissertation, Free University of Berlin. 2003. Zuba D, Sekula K. 25C-NBOMe -- new representative of potent hallucinogenic substances. Forensic Toxicology. 2020;38:530-537. US DEA. Schedules of Controlled Substances: Temporary Placement of Three Synthetic Phenethylamines Into Schedule I. Federal Register. 2013;78(221):68716-68719.
Harm Reduction
Ehrlich Reagent Test — Critical
Test any blotter sold as or suspected to be LSD with an Ehrlich reagent before use. LSD turns purple-violet. 25C-NBOMe contains no indole and producesno color change — a negative Ehrlich test indicates the substance does not contain an indole alkaloid and raises the possibility of NBOMe or other phenethylamine substitution. A negative Ehrlich should be treated as a serious warning.
Send a sample to EcstasyData.org, The Loop, or a comparable mass spectrometry testing service for definitive identification.
Sublingual Administration Only
25C-NBOMe requires sublingual or buccal administration. Hold blotter under the tongue for 15–20 minutes. The compound is essentially inactive if swallowed.
Dose Strictly
- Active threshold: ~200–400 μg
- Common: 500–1,000 μg
- Strong/high risk: 1,000+ μg
- Without quantitative testing, exact blotter dose is unknown. Experienced users recommend starting with a portion of a single blotter and waiting the full onset period (up to 60 minutes) before considering any additional dose.
Never Redose
Premature redosing is a primary driver of NBOMe-related serious adverse events. If no effects appear within 60 minutes, do not add more — the compound may be slowly absorbing or may be inactive for physiological reasons. Adding a second dose before the first takes effect frequently produces overwhelming and dangerous intensification.
Monitor Physiological Warning Signs
- Cold, pale, or blue fingers, toes, or lips → warming environment, cease exertion, monitor
- Chest pain or tightness → call emergency services
- Temperature rising with exertion → cooling measures immediately
- Seizure → emergency services, recovery position
Emergency Response
Inform emergency services of the suspected substance. Benzodiazepines are appropriate for anxiety and agitation. Report vasoconstriction, hyperthermia, and seizures to medical personnel — specific clinical interventions are available.
Toxicity & Safety
Confirmed Fatalities
25C-NBOMe is directly associated with confirmed human fatalities. Reports of fatal outcomes include cardiovascular collapse, seizures, hyperthermia, and multi-organ failure. The compound was identified in postmortem toxicology in multiple death cases in Europe and North America during 2012–2016.
Mechanism of Severe Toxicity
The primary mechanisms of life-threatening toxicity are:
- Severe vasoconstriction — alpha-adrenergic receptor activation; can progress to vascular compromise, cardiac ischemia, and cardiovascular collapse at high doses
- Hyperthermia — dangerously elevated core body temperature, particularly with physical exertion
- Tonic-clonic seizures — documented in multiple cases of severe NBOMe toxicity
- Rhabdomyolysis — skeletal muscle breakdown secondary to hyperthermia and seizures; leads to renal failure
Narrow Therapeutic Window
Like all NBOMe compounds, 25C-NBOMe has a narrow dose window between desired psychedelic effects and dangerous physiological toxicity. This window is compressed further by:
- Batch-to-batch variation in blotter potency
- Individual pharmacokinetic variation (body weight, CYP450 genotype)
- Concurrent substance use (particularly stimulants)
Cardiovascular Effects
Significant tachycardia and hypertension are consistent effects. Those with pre-existing cardiovascular conditions are at dramatically elevated risk.
Drug Interactions
- Stimulants — Absolutely contraindicated; synergistic vasoconstriction and cardiac risk
- Lithium — Absolutely contraindicated for all psychedelics
- MAOIs — Avoid; serotonin syndrome risk
- Cannabis — Unpredictably amplifies intensity and psychological adverse events
Contraindications
- Cardiovascular disease, hypertension, or any vascular disorder (absolute contraindication)
- Personal or family history of psychotic disorders
- Concurrent use of stimulants, lithium, or MAOIs
Addiction Potential
not habit-forming
Overdose Information
LD50fatal at heavy dosages.
It is advised that due to 25C-NBOMe's extreme potency it should not be insufflated (snorted) as this method of administration has been attributed to several fatal overdoses due to improper dosing.
- Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
- Canada: 25C-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
- China: As of October 2015 25C-NBOMe is a controlled substance in China.
- Germany: 25C-NBOMe is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
- Israel: The NBOMe series of psychoactives became controlled in Israel in May, 2013.
- Italy: 25C-NBOMe is a Schedule 1 controlled substance in Italy, meaning it is illegal to possess, distribute, and manufacture.
- Japan: 25C-NBOMe is a narcotic drug in Japan effective November 1st, 2015.
- Latvia: 25C-NBOMe is a Schedule I controlled substance.
- New Zealand: 25C-NBOMe was sold as a designer drug in New Zealand in early 2012, but was withdrawn from sale after a statement by Associate Health Minister Peter Dunne that 25C-NBOMe would be considered to be substantially similar in chemical structure to the illegal hallucinogen DOB, and was therefore a Class C controlled drug analogue.
- Russia: Russia became the first country to regulate the NBOME class. The entire NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011.
- Sweden: 25C-NBOMe is classed as Schedule I.
- Switzerland: 25C-NBOMe is a controlled substance specifically named under Verzeichnis D.
- Turkey:** 25C-NBOMe is a classed as drug and is illegal to possess, produce, supply, or import.
- United Kingdom: 25C-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzy
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Tolerance
| Full | almost immediately after ingestion |
| Half | 7 days |
| Zero | 14 days |
Cross-tolerances
Legal Status
Austria: Since June 26, 2019, 25C-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
Canada: 25C-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
China: As of October 2015 25C-NBOMe is a controlled substance in China.
Germany: 25C-NBOMe is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Israel: The NBOMe series of psychoactives became controlled in Israel in May, 2013.
Italy: 25C-NBOMe is a Schedule 1 controlled substance in Italy, meaning it is illegal to possess, distribute, and manufacture.
Japan: 25C-NBOMe is a narcotic drug in Japan effective November 1st, 2015.
Latvia: 25C-NBOMe is a Schedule I controlled substance.
New Zealand: 25C-NBOMe was sold as a designer drug in New Zealand in early 2012, but was withdrawn from sale after a statement by Associate Health Minister Peter Dunne that 25C-NBOMe would be considered to be substantially similar in chemical structure to the illegal hallucinogen DOB, and was therefore a Class C controlled drug analogue.
Russia: Russia became the first country to regulate the NBOME class. The entire NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011.
Sweden: 25C-NBOMe is classed as Schedule I.
Switzerland: 25C-NBOMe is a controlled substance specifically named under Verzeichnis D.
Turkey:** 25C-NBOMe is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: 25C-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.
United States: Several NBOMe series compounds will be temporarily scheduled in the United States for 2 years with the possibility of an additional year. The temporary scheduling applies to 25C-NBOMe, 25B-NBOMe, and 25I-NBOMe.
Responsible use
Psychedelics
Phenethylamines
25I-NBOMe
25B-NBOMe
25C-NBOMe (Wikipedia)
25C-NBOMe (Erowid Vault)
25C-NBOMe (Isomer Design)
25C-NBOMe (Drugs-Forum)
Discussion
25C-NBOMe, broken down and described (Disregard Everything I Say)
Experience Reports (1)
Tips (5)
Keep a benzodiazepine like alprazolam on hand as an emergency trip abort tool when using 25C-NBOMe. Even just knowing you have one available provides psychological reassurance. It will not fully end the trip but significantly reduces intensity.
Use a milligram scale to weigh 25C-NBOMe if it comes as a powder. Eyeballing doses of potent psychedelics is irresponsible. A quality 0.001g scale costs under $30 and could prevent a seriously overwhelming experience.
Integration is just as important as the experience itself. After using 25C-NBOMe, take time to journal, reflect, or discuss the experience. Insights from psychedelic states can be powerful but need conscious effort to apply to daily life.
Do not combine 25C-NBOMe with lithium (seizure risk), tramadol (seizure/serotonin syndrome risk), or cannabis at higher doses unless very experienced. Cannabis dramatically intensifies and can destabilize a psychedelic experience.
Always test 25C-NBOMe with an Ehrlich reagent before use. A positive reaction (purple/pink color change) confirms the presence of an indole/lysergamide compound. No reaction could indicate a dangerous substitute like an NBOMe.
See Also
Same Class
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 25C-NBOMe - TripSit Factsheet
TripSit factsheet for 25C-NBOMe
tripsit - 25C-NBOMe - Wikipedia
Wikipedia article on 25C-NBOMe
wikipedia